| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C20H16N6 |
| Purity | |
| Activity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity, with an EC50 of 2 μM. It also inhibits ATM phosphorylation and DNA repair, and selectively enhances toll-like receptor 3 (TLR3)- and RIG-I-like receptor (RLR)-ligand-induced IFN-β gene expression and antiviral response[2]. It additionally inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner[3] and has significant radiosensitizing effects on cervical cancer cells[4]. It is supplied as a brown to green solid (C20H16N6, MW 340.38) at 98.50% purity.
Physical & Chemical Properties
| CAS Number | 293762-45-5 |
|---|---|
| Molecular Formula | C20H16N6 |
| Molecular Weight | 340.38 g/mol |
| Purity | 98.50% |
| Appearance | Solid |
| Color | Brown to breen |
| SMILES | NC1=CC=C2C(N=C(C3=CC=C4C(N=C(C5=CC=C(N)C=C5)N4)=C3)N2)=C1 |
| Target | Amyloid β42, ATM, Protein phosphatase 5 |
| Signaling Pathway | Neuronal Signaling; PI3K/Akt/mTOR; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Apoptosis |
| Bioactivity Class | Apoptosis |
| Solubility | In Vitro: DMSO: 41.67 mg/mL (122.42 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 41.67 mg/mL (122.42 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | 2.08 mg/mL (6.11 mM); suspension; requires sonication |
| How to prepare | Gives a suspension at 2.08 mg/mL. The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (6.11 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
Compared with control HeLa and ME-180 cells, Ro 90-7501 significantly enhances radiosensitivity. After irradiation, Ro 90-7501 significantly raises apoptosis and disrupts the cell cycle. Following irradiation, phosphorylation of ATM and its downstream proteins (H2AX, Chk1, and Chk2) is suppressed by Ro 90-7501[1]. RO 90-7501 alone does not affect IFN-β or NFκB promoter activity, but it significantly enhances poly I:C-induced IFN-β promoter activation and dose-dependently inhibits NFκB activation. Cells treated with RO 90-7501 show significantly enhanced antiviral activity of poly I:C[2].
In Vivo
In female BALB/c nude mice, Ro 90-7501 (5 μg/g; intraperitoneal injection; daily; for 21 days) significantly delays tumor growth and significantly decreases tumor volume[1].
| Animal Model | Female BALB/c nude mice (8-week-old) with HeLa cells under irradiation[1] |
|---|---|
| Dosage | 5 μg/g |
| Administration | Intraperitoneal injection; daily; for 21 days |
| Result | Tumor growth was significantly delayed in the combination group. Tumor volume was also significantly decreased in the irradiation group. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Ro 90-7501 suppresses colon cancer progression by inducing immunogenic cell death and promoting RIG-1-mediated autophagy. Int Immunopharmacol 2024 Nov 15;143(Pt 3):113631. PMID: 39549547
Inhibitors of APE1 redox and ATM synergistically sensitize osteosarcoma cells to ionizing radiation by inducing ferroptosis. Int Immunopharmacol 2024 Sep 30:139:112672. PMID: 39032469
Modified 5-aminolevulinic acid photodynamic therapy (M-PDT) inhibits cutaneous squamous cell carcinoma cell proliferation via targeting PP2A/PP5-mediated MAPK signaling pathway. Int J Biochem Cell Biol 2021 Aug:137:106036. PMID: 34217813
